<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749619</url>
  </required_header>
  <id_info>
    <org_study_id>TAURO 070908</org_study_id>
    <nct_id>NCT00749619</nct_id>
  </id_info>
  <brief_title>Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Galilee Hospital-Nahariya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Galilee Hospital-Nahariya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Addition of Heparin to the Catheter Lock Solution (CLS): Taurolock-TM will improve the
      vascular patency compared to Taurolock-TM alone , in hemodialysis patients with Tunneled
      Cuffed Catheter(TCC) as vascular access.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacteremia and thrombosis are the major complications of TCC used for
      hemodialysis.Instilation of CLS containing antibiotic-anticoagulant solution in the end of
      each dialysis session till the next dialysis ,can prevent Catheter related bacteremia
      (CRB).In previous study in our department, Taurolock-TM decreased the rate of CRB but
      increased the incidence of catheter malfunction.

      The aim of the study is to investigate the influence of of Heparin addition to CLS-Taurolock-
      TM ( Taurolidine &amp;citrate 4%) in prevention of catheter patency problems in HD patients with
      TCC, in addition to CRB prevention.

      Methods : Patients with newly inserted TCC for HD enrolled and randomized to receive one of
      three CLS types : group 1- Taurolock-TM, Group 2 - Taurolock-TM and Heparin , Group 3-
      Heparin .Patients were followed for 6 monthes.

      The objective of the study is to investigate the effect of Taurolock TM with heparin on the
      rate of CRB and vascular patency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <condition>End Stage Renal Disease</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Catheter Lock Solution Taurolidine and Citrate</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Catheter Lock Solution :Taurolidine and Citrate and Heparin</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Catheter Lock Solution : Heparin</intervention_name>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodialysis patients with new TCC

          -  Informed Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Western Galilee Hospital</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>September 8, 2008</last_update_submitted>
  <last_update_submitted_qc>September 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2008</last_update_posted>
  <keyword>Tunneled Cuffed Catheter</keyword>
  <keyword>Catheter Lock Solution</keyword>
  <keyword>Catheter Related Bacteremia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Taurolidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

